|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||159.26 - 164.68|
|52-week range||142.81 - 256.80|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||2.88 (1.76%)|
|1y target est||215.95|
Teva Pharmaceuticals (TEVA) reported a GAAP (generally accepted accounting principles) operating loss of $13 billion in fiscal 4Q17, which it reported on February 8, 2018. This difference was the result of significant impairment charges related to Teva’s US generics business in fiscal 4Q17. In fiscal 4Q17, Teva recorded a non-GAAP adjustment of $15.3 billion, ~$11 billion of which was due to the impairment of goodwill related to the company’s US generics business.
Looks can be deceiving when it comes to the drugmaker Allergan. New competition to its top product, Botox, and the surprise loss of patent exclusivity for its second biggest, the dry-eye treatment Restasis, have left investors with worry lines. The valuation is low enough that most of the bad news surrounding Allergan appear already priced in.
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines
Allergan Plc Chief Executive Officer Brent Saunders received $32.8 million of compensation for 2017, a year when shares of the drugmaker slumped.
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.
Allergan tanked to a five-year low Thursday after Mylan and Revance announced their plan to bring a Botox copycat to the market.
Allergan Plc faces another risk after the generic drugmaker Mylan NV announced plans to align itself with a small-cap competitor and develop a biosimilar to Allergan’s top-selling wrinkle treatment and ...
WASHINGTON (AP) — The Justice Department said Tuesday it will support local officials in hundreds of lawsuits against manufacturers and distributors of powerful opioid painkillers that are fueling the nation's drug abuse crisis.
Allergan likely expected to have the patent challenges dismissed under a deal with a New York State American Indian tribe.